Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: Rationale for their use in clinical cardiology

Mini-Reviews in Medicinal Chemistry

Volumn 4, Issue 7, 2004, Pages 703-709

  Rossi, Marco L ^a   Zavalloni, D ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Acute coronary syndromes; Atherosclerotic plaque; Glycoprotein IIb IIIa receptor; Percutaneous coronary intervention; Platelet aggregation inhibitors

Indexed keywords

ABCIXIMAB; ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; ORBOFIBAN; SIBRAFIBAN; TIROFIBAN; TROPONIN I; XEMILOFIBAN;

BLEEDING DISORDER; CARDIOLOGY; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; HEART MUSCLE ISCHEMIA; HUMAN; IC 50; PHARMACODYNAMICS; PROTEIN FUNCTION; RESTENOSIS; REVIEW; THROMBOCYTE AGGREGATION; THROMBOSIS;

ANIMALS; BINDING SITES; CARDIOVASCULAR DISEASES; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 4344629332     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Hynes, R.O. Cell 1987, 48, 549-50.
2. Duperray, A.; Troesch, A.; Berthier, R.; Chagnon, E.; Frachet, P.; Uzan, G.; Marguerie, G. Blood 1989, 74, 1603-11.
3. Poncz, M.; Eisman, R.; Heidenreich, R.; Silver, S.M.; Vilaire, G.; Surrey, S.; Schwartz, E.; Bennett, J.S., J. Biol. Chem. 1987, 262, 8476-82.
4. Fitzgerald, L.A.; Steiner, B.; Rall, S.C. Jr.; Lo, S.S.; Phillips, D.R. J. Biol. Chem. 1987, 262, 3936-9
5. Philips, D.R.; Charo, I.F.; Parise, L.V.; Fitzgerald, L.A. Blood 1988, 71, 831-43
6. Kunicki, T.J.; Pidard, D.; Rosa, J.P.; Nurden, A.T. Blood 1981, 58, 268-78.
7. Fujimura, K.; Philips, D.R. J. Biol. Chem. 1983, 258, 10247-52.
8. Becker R.C. Fibrinolytic and antithrombotic therapy, theory, practice and management. Oxford University Press, Inc. 2000.
9. Lefkovits, J.; Plow, E.F.; Topol, E.J. N. Engl. J. Med. 1995, 332, 1553-59.
10. Philips, D.R.; Agin, P.P. J. Clin. Invest. 1977, 60, 535-45.
11. Rao, A.K.; Holmsen, H. Semin. Haematol. 1986, 23, 102-18.
12. Phillips, D.R.; Charo, I.F.; Parise, L.V.; Fitzgerald, L.A. Blood 1998, 71, 831-43.
13. Byzova, T.V.; Plow, E.F. J. Biol. Chem. 1997, 272, 27183-88.
14. Fuster, V.; Badimon, L.; Badimon, J.J.; Chesbero, J.H. N. Engl. J. Med. 1992, 326, 242-50.
15. Fuster, V.; Badimon, L.; Badimon, J.J.; Chesbero, J.H. N. Engl. J. Med. 1992, 326, 310-18.
16. Wagner, C.L.; Macelli, M.A.; Neblock, D.S.; Weisman, H.F.; Coller, B.S.; Jordan, R.E. Blood 1996, 88, 907-914.
17. Fernandez-Ortiz, A.; Badimon, J.J.; Falk, E.; Fuster, V.; Meyer, B.; Mailmac, A.; Weng, D.; Shah, P.K.; Badimon, L. J. Am. Coll. Cardiol. 1994, 23, 1562-69.
18. Huges, P.E.; Pfaff, M. Trends. Cell. Biol. 1998, 8, 359-64.
19. Humphries, M.J. Curr. Opin. Cell. Biol. 1996, 8, 632-40.
20. Coller, B.S. Platelets in Cardiovascular thrombosis and thrombolysis. Fozzard, H.A.; Haber, E.; Jennings, R.B.; Katz, A.M.; Morgan, H.E., eds. The heart and cardiovascular system, Scientific foundations. 2nd ed. Vol. 1 Raven Press, New York, 1991, 219-73
21. Kleiman, N.S.; Raizner, A.E.; Jordan, R.; Wang, A.L.; Norton, D.; Mace, K.F.; Joshi, A.; Coller, B.S.; Weisman, H.F. J. Am. Coll. Cardiol. 1995, 26, 1665-71.
22. Mascelli, M.A.; Worley, S.; Veriabo, N.J.; Lance, E.T.; Mack, S.; Schaible, T.; Weisman, H.F.; Jordan, R.E. Circulation 1997, 96, 3860-66.
23. Shattil, S.J.; Ginsberg, M.H. J. Clin. Invest. 1997, 100, S91-95.
24. Kloczewiak, M.; Timmons, S, Hawiger, J. Thromb. Res. 1983, 29, 249-55.
25. Kloczewiak, M, Timmons, S, Lukas, T.J.; Hawiger, J. Biochemistry 1984, 23, 1767-74.
26. Farrell, D.H.; Thiagarajan, P.; Chung, D.W.; Davie, E.W. Proc. Natl. Acad. Sci. USA 1992, 89, 10729-32.
27. Plow, E.F.; Marguerie, G.; Ginsberg, M. Biochem. Pharmacol. 1987, 36, 4035-40.
28. Yamada, T.; Matsushima, M.; Inaka, K.; Ohkubo, T.; Uyeda, A.; Maeda, T.; Titani, K.; Sekiguchi, K.; Kikuchi, M. J. Biol. Chem. 1993, 268, 10588-92.
29. Weisel, J.W.; Nagaswami, C.; Vilaire, G.; Bennett, J.S. J. Biol. Chem. 1992, 267, 16637-43.
30. Pierschbacher, M.D.; Ruoslahti, E. Nature 1984, 309, 30-3
31. Topol, E.J. N. Engl. J. Med. 1997, 336, 1621-28
32. Farrell, D.H.; Thiagarajan, P.; Chung, D.W.; Davie, E.W. Natl. Acad. Sci. USA 1992, 89, 10729-10732.
33. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990, 336, 827-30.
34. Schwartz, L.; Bourassa, M.G.; Lesperance, J.; Aldridge, H.E.; Kazim, F.; Salvatori, V.A.; Henderson, M.; Bonan, R.; David, P.R. N. Engl. J. Med. 1988, 318, 1714-9.
35. Kleiman, N.S. Am. Heart J. 1999, 138, S263-75
36. Gold, H.K.; Gimple, L.W.; Yauda, T.; Leinbach, R.C.; Werner, W.; Holt, R.; Jordan, R.; Berger, H.; Collen, D.; Coller, B.S. J. Clin. Invest. 1990, 86, 651-659.
37. O'Neill, W.W.; Serruys, P.; Knudtson, M.; Van Es, G.A.; Timmis, G.C.; Van der Zwaan, C.; Kleiman, J.; Gong, J.; Roecker, E.B.; Dreiling, R.; Alexander, J.C.; Anders, R. N. Engl. J. Med. 2000, 342, 1316-24.
38. Cannon, C.P.; McCabe, C.H.; Wilcox, R.G.; Langer, A.; Caspi, A.; Bernik, P.; Lopez-Sendon, J.; Toman, J.; Charlesworth, A.; Anders, R.J.; Alexander, J.C.; Skene, A.; Braunwald, E. Circulation 2000, 102, 149-156.
39. The SYMPHONY Investigators. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Comparison of Sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes, a randomised trial. Lancet 2000, 355, 337-345.
40. Coller, B.S, Peerschke, E.I, Scudder, L.E.; Sullivan C.A. J. Clin. Invest. 1983, 72, 325-38.
41. Jordan, R.E.; Mascelli, M.A.; Nakada, M.T.; Weisman, H.F. Pharmacology and clinical development of abciximab (c7E3 Fab, ReoPro). In: New therapeutic agents in thrombosis and thrombolysis. Gasahara, A.A.; Losaelzo, J. eds. New York, Marcel Dekker, 1997, 291-313.
42. Topol, E.J.; Byzova, T.V.; Plov, E.F. Lancet 1999, 353, 227-31.
43. Reverter, J.; Beguin, S.; Kessels, R.; Hemker, H.; Coller, B. J. Clin. Invest. 1996, 88, 863-874.
44. Merlini, P.A.; Repetto, A.; Lombardi, A.; Vetrano, A.; Fetiveau, R.; Cavallini, C.; Sappe', D.; Salvioni, A.; Canziani, R.; Savonitto, S.; Mannucci, P.M.; Ardissino, D. Circulation 2002, 105, 928-32.
45. Mascelli, M.A.; Lance, E.T.; Damaraju, L.; Wagner, C.L.; Weisman, H.F.; Jordan, R.E. Circulation 1998, 97, 1680-88.
46. Scarborough, R.M.; Hsu, M.A.; Teng, W. Arterioscler. Thromb. 1991, 11, 1591a
47. Scarborough, R.M.; Rose, J.W.; Hsu, M.A.; Phillips, D.R.; Fried, V.A.; Campbell, A.M.; Nannizzi, L.; Charo, I.F. J. Biol. Chem. 1991, 266, 9359-62.
48. Scarborough, R.M.; Naughton, M.A.; Teng, W.; Rose, J.W.; Phillips, D.R.; Nannizzi, L.; Arfsten, A.; Campbell, A.M.; Charo, I.F. J. Biol. Chem. 1993, 268, 1066-73.
49. Alton, K.B.; Kosoglou, T.; Baker, S.; Affrime, H.B.; Cayen, M.N.; Patrick, J.E. Clin. Ther. 1998, 20, 307-23.
50. Sambol, N.C.; Tcheng, J.E.; Kitt, M. Clin. Pharmacol. Ther. 1996, 59, 150.
51. Kereiakes, D.J.; Kleiman, N.S.; Ambrose, J.; Cohen, M.; Rodriguez, S.; Palabrica, T.; Herrmann, H.C.; Sutton, J.M.; Weaver, W.D.; McKee, D.B.; Fitzpatrick, V.; Sax, F.L. J. Am. Coll. Cardiol. 1996, 27, 536-42.
52. Peerlinck, K.; De Lepeleire, I.; Goldberg, M.; Farrell, D.; Barrett, J.; Hand, E.; Panebianco, D.; Deckhin, H.; Vermylen, J.; Arnout, J. Circulation 1993, 88, 1512-7.
53. Merck and Co. Inc. Aggrastat (tirofiban hydrochlororide) prescribing information. West Point, PA, USA, 1998.
54. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 1998, 338, 1488-97.
55. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation, the GUSTO IV-ACS randomised trial. Lancet 2001, 357, 1905-14.
56. Davi, G.; Gresele, P.; Violi, F.; Basili, S.; Catalano, M.; Giammarresi, C.; Volpato, R.; Nenci, G.C.; Ciabattoni, G.; Patrono, C. Circulation 1997, 96, 69-75.
57. Newby, L.K.; Ohman, E.M.; Christenson, R.M.; Moliterno, D.J.; Harrington, R.A.; White, H.D.; Armstrong, P.W.; Van de Werf, F.; Pfisterer, M.; Hasselblad, V.; Califf, R.M.; Topol, E.J. Circulation 2001, 103, 2891-6.
58. Peter, K.; Schwarz, M.; Ylanne, J.; Kohler, B.; Moser, M.; Nordt, T.; Salbach, P.; Kubler, W.; Bode, C. Blood 1998, 92, 3240-3249.
59. Cox, D.; Smith, R.; Quinn, M.; Theroux, P.; Crean, P.; Fitzgerald, D.J. J. Am. Coll. Cardiol. 2000, 36, 1514-1519
60. Li, N.; Hu, H.; Lindqvist, M.; Wikstrom-Jonsson, E.; Goodall, A.H.; Hjemdahl, P. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 2702-2708.